The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis
Abstract Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies until August 10, 2021. The data on ov...
Saved in:
Main Authors: | Chunmei Zhang (Author), Wancheng Zhao (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
by: Siyuan Zeng, et al.
Published: (2023) -
Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
by: Lili Gao, et al.
Published: (2021) -
Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer
by: Xue Zhang, et al.
Published: (2024) -
Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis
by: Yuanyuan Yang, et al.
Published: (2023) -
Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
by: Nicholas Adrianto, et al.
Published: (2024)